Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.
A newly launched UK biotech is looking to develop a new approach to immunotherapy, based around a seemingly paradoxical idea that stimulating cancer makes them more visible to the body’s de